Safety and efficacy of formoterol/tiotropium bromide and formoterol/glycopyrronium combination in patients with chronic obstructive pulmonary disease

Siraj Ahmad; Jameel Ahmad; Farida Ahmad; Zuber Ahmad

doi:10.18203/2320-6012.ijrms20230868

Authors

Siraj Ahmad Department of Pharmacology, Jawahar Lal Nehru Medical College and Hospital, AMU, Aligarh, Uttar Pradesh, India
Jameel Ahmad Department of Pharmacology, Jawahar Lal Nehru Medical College and Hospital, AMU, Aligarh, Uttar Pradesh, India
Farida Ahmad Department of Pharmacology, Jawahar Lal Nehru Medical College and Hospital, AMU, Aligarh, Uttar Pradesh, India
Zuber Ahmad Department of Tuberculosis and Respiratory Diseases, Jawahar Lal Nehru Medical College and Hospital, AMU, Aligarh, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20230868

Keywords:

Tiotropium, Glycopyrrolate, Formoterol, Symptom score, COPD assessment test

Abstract

Background: Chronic obstructive pulmonary disease is characterized by a progressive development of airflow limitation that is not fully reversible. The study investigated the efficacy and safety of formoterol/tiotropium bromide and formoterol/glycopyrronium combination in patients with chronic obstructive pulmonary disease. Glycopyrrolate, a long-acting anti-muscarinic agent is recently approved for the maintenance therapy of chronic obstructive pulmonary disease in combination with formoterol. However, the studies on glycopyrrolate along with long-acting beta 2 agonist, particularly in Indian patients are limited. Hence it was considered worthwhile to determine safety and efficacy of fixed dose combinations of formoterol/ tiotropium vs. formoterol/glycopyrrolate in grade-2 patients of chronic obstructive pulmonary disease patients.

Methods: Efficacy and safety of formoterol/glycopyrrolate and formoterol/tiotropium were compared in Grade-2 patients. Total 68 patients were analysed and the efficacy of treatment was determined by Spirometry, Chronic Obstructive Pulmonary Disease Assessment Test score and Symptom score at day zero (before therapeutic intervention) and at two weeks of interval till 12 weeks.

Results: The treatment with inhaled combination of formoterol/glycopyrrolate and formoterol/tiotropium has shown an improvement in spirometric variable Forced Expiratory Volume (in one second) decrease in mean Symptom score and COPD Assessment Test score among the grade-2 Chronic Obstructive Pulmonary Disease patients.

Conclusions: Combination therapy of formoterol/glycopyrrolate is non-inferior to formoterol/tiotropium in terms of efficacy and safety profile of patients with chronic obstructive pulmonary disease.

Metrics

Metrics Loading ...

References

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164.

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128.

Pulmonary disease. Available at: https://www.who. int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). Accessed on 20 November 2022.

Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2197-223.

Hossain MM, Sultana A, Purohit N. Burden of chronic obstructive pulmonary disease in India: status, practices and prevention. Int J Pulm Respir Sci. 2018; 2(5):1-4.

Salvi S, Agrawal A. India needs a national COPD prevention and control programme. J Assoc Physicians India. 2012;60(1):5-7.

Montuschi P, Ciabattoni G. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem. 2015;58(10):4131-64.

Shameem M, Akhtar J, Ahmad A, Ahmad J. Efficacy of Fixed dose combination of Formoterol and Fluticasone propionate dry powder inhaler (DPI), in management of Partly controlled & Uncontrolled asthma in 5-17 yr group. Int J Sci Res. 2014;3(5):415-8.

Currie GP, Lipworth BJ. Inhaled treatment for chronic obstructive pulmonary disease: what’s new and how does it fit?. QJM Int J Med. 2015;109(8):505-12.

Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;10(10): CD010177.

Alam M, Ahmad J, Kumar A, Shameem M. Efficacy and safety of inhaled indacaterol and tiotropium in patients of chronic obstructive pulmonary disease. IJPI. 2020;10(2):217-20.

Melani AS. Long-acting muscarinic antagonists. Expert Rev Clin Pharmacol. 2015;8(4):479-501.

Bartels C, Looby M, Sechaud R, Kaiser G. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. Br J Clin Pharmacol. 2013;76(6):868-79.

prescribing Information. Available at: https://www. accessdata.fda.gov/drugsatfda_docs/label/2015/207923lbl.pdf. Accessed on 20 November 2022.

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts EA. Naranjo ADR probability scale. Clin Pharmacol Ther. 1981;30:239-45.

Kerwin E, Donohue JF, Goodin T, Tosiello R, Wheeler A, Ferguson GT. Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respir Med. 2017;132:238-50.

Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450-504.

Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347-65.

O’Reilly J, Jones MM, Parnham J, Lovibond K, Rudolf M. Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ. 2010;340: c3134.

Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;7:CD009285.

Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;11(11):CD002309.

Kistemaker LE, Oenema TA, Meurs H, Gosens R. Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD. Life Sci. 2012;91(22): 1126-33.

Frith PA, Thompson PJ, Ratnavadivel R, Chang CL, Bremner P, Day P. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax. 2015;70(6):519-27.

Chapman KR, Beeh KM, Beier J, Bateman ED, D'Urzo A, Nutbrown R, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med. 2014;14:4.

Kerwin E, Hébert J, Gallagher N, Martin C, Overend T, Alagappan VK, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012; 40(5):1106-14.

Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648-54.

Karloh M, Fleig Mayer A, Maurici R, Pizzichini MMM, Jones PW, Pizzichini E. The COPD Assessment Test: What Do We Know So Far?: A Systematic Review and Meta-Analysis About Clinical Outcomes Prediction and Classification of Patients Into GOLD Stages. Chest. 2016;149(2):413-25.

Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, et al. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax. 2015; 70(4):311-9.

Moitra S, Bhome AB, Brashier BB. Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date. Drug Des Devel Ther. 2015;9:1989-99.

Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med. 2008;102(7):1033-44.